startups digital health weight loss glp-1 Beyond Ozempic: How Indian are building around drugs Software development for GLP-1 and

This delivery system solves the problem that makes other treatments fail

To summarize, on one hand the modest upwards trajectory of the obese and diabetic population provides a fertile ground for Pharma companies to sell more for the years to come, however, downside risks remain, including: pricing, compounders and overall competition, which will make it hard for companies like Novo and Lilly to maintain their growth

As of 2021, approximately 537 million adults were living with diabetes, and about 1.4 million new cases of diabetes are diagnosed in the United States every year

Reconstitution ratios

A core highlight includes the Phase 3 ACHIEVE trial results for Foundayo, an oral small-molecule GLP-1 receptor agonist taken without food or water restrictions

Eur J Intern Med